Protecting the acutely ischemic myocardium beyond reperfusion therapies: Are we any closer to realizing the dream of infarct size elimination?

Archives des Maladies du Coeur et des Vaisseaux

Volumn 100, Issue 9, 2007, Pages 794-802

  Tissier, R ^a   Cohen, M V ^b   Downey, J M ^b  

^a ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Myocardial infarction; Reperfusion; RISK pathway

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; BAY 606583; CALCIUM; GLUCOSE; INSULIN; NICORANDIL; POTASSIUM; REACTIVE OXYGEN METABOLITE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HEART INFARCTION SIZE; HUMAN; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 36049003254     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353: 1547-57.
2. Schömig A, Ndrepepa G, Kastrati A. Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. Eur Heart J 2006; 27: 1900-7.
3. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
4. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-51.
5. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-43.
6. Stein AB, Tang X-L, Guo Y, Xuan Y-T, Dawn B, Bolli R. Delayed adaptation of the heart to stress: late preconditioning. Stroke 2004; 35 (Suppl 1): 2676-9.
7. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15: 69-75.
8. Yang X-M, Krieg T, Cui L, Downey JM, Cohen MV. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 2004; 36: 411-21.
9. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-6.
10. Yang X-M, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006; 101: 311-8.
11. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-15.
12. Zhao Z-Q, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 2003; 285: H579-88.
13. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJGM. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007; 94: 344-55.
14. Magnesium In Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium In Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189-96.
15. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
16. Santoro GM, Antoniucci D, Bolognese L, et al. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J 2000; 140: 891-7.
17. Bär FW, Tzivoni D, Dirksen MT, et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J 2006; 27: 2516-23.
18. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38: 1644-50i.
19. Tsujita K, Shimomura H, Kawano H, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 481-4.
20. Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994; 89: 1982-91.
21. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol 1989; 21: 1241-51.
22. Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40: 1199-204i.
23. Rusnak JM, Kopecky SL, Clements IP, et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001; 88: 482-7.
24. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-90.
25. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-83.
26. Armstrong PW, Mahaffey KW, Chang W-C, et al. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am Heart J 2006; 151: 787-90.
27. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997; 96: 192-201.
28. Jonassen AK, Sack MN, Mjøs OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001; 89: 1191-8.
29. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin- potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-46.
30. Ceremu y ski L, Budaj A, Czepiel A, et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999; 13: 191-200.
31. van der Horst ICC, Zijlstra F, van't Hof AWJ, et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. The Glucose-Insulin-Potassium Study: a randomized trial. J Am Coll Cardiol 2003; 42: 784-91.
32. Timmer JR, Svilaas T, Ottervanger JP, et al. Glucose-insulin- potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol 2006; 47: 1730-1.
33. Jonassen AK, Aasum E, Riemersma RA, Mjøs OD, Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000; 14: 615-23.
34. The European Myocardial Infarction Project - Free Radicals Group (EMIP-FR Group). Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy: a double-blind, placebo-controlled, randomized trial. Eur Heart J 2000; 21: 1537-46.
35. Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol 2006; 290: H441-9.
36. 2b receptor cascade. Cardiovasc Res 2006; 70: 308-14.
37. 2A receptor agonist, in reperfused canine myocardium. Am J Physiol 2005; 288: H1851-8.
38. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987; 76: 1135-45.
39. Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996; 31: 711-8.
40. Goto M, Miura T, Iliodoromitis EK, et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 1991; 25: 943-9.
41. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 1998; 286: 611-8.
42. 2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005; 111: 2190-7.
43. 2b- during early reperfusion. J Mol Cell Cardiol 2007; 43: 262-71.
44. 3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol 2003; 285: H607-13.
45. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711-20.
46. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.
47. Cohen MV, Downey JM. AMISTAD trials: possible reasons for lack of success. J Am Coll Cardiol 2006; 47: 1236.
48. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 2003; 146: 146-52.
49. Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 2006; 70: 264-73.
50. + channel and protein kinase C activation. Basic Res Cardiol 2006; 101: 180-9.
51. Cohen MV, Yang X-M, Downey JM. The pH hypothesis of post-conditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007; 115: 1895-903.
52. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112: 2143-8.
53. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K. 'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 2007; 102: 274-8.
54. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-60.
55. Juhaszova M, Zorov DB, Kim S-H, et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113: 1535-49.
56. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase dependent pathway is cardioprotective. Circ Res 2002; 90: 377-9.
57. Imagawa J-i, Baxter GF, Yellon DM. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 1998; 31: 74-9.
58. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75.
59. Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004; 148: E15.
60. Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (JWIND-ANP). Circ J 2004; 68: 95-100.
61. Kitakaze M, Asakura M, Shintani Y, et al. Large-scale trial using atrial natriuretic peptide or nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. Circulation 2006; 114: 2425-6.
62. Chien GL, Wolff RA, Davis RF, van Winkle DM. "Normothermic range" temperature affects myocardial infarct size. Cardiovasc Res 1994; 28: 1014-7.
63. Miki T, Liu GS, Cohen MV, Downey JM. Mild hypothermia reduces infarct size in the beating rabbit heart: a practical intervention for acute myocardial infarction? Basic Res Cardiol 1998; 93: 372-83.
64. Tissier R, Hamanaka K, Kuno A, Parker JC, Cohen MV, Downey JM. Total liquid ventilation provides ultra-fast cardioprotective cooling. J Am Coll Cardiol 2007; 49: 601-5.
65. Magid DJ, Wang Y, Herrin J, et al. Relationship between time of day, day of week, timeliness of reperfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial infarction. JAMA 2005; 294: 803-12.
66. Felberg RA, Krieger DW, Chuang R, et al. Hypothermia after cardiac arrest: feasibility and safety of an external cooling protocol. Circulation 2001; 104: 1799-804.
67. Ly HQ, Denault A, Dupuis J, et al. A pilot study: the Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J 2005; 150: 933.e9-13.
68. Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1928-34.
69. Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol 2004; 93: 636-9.